Bernstein analyst William Pickering maintains $Regeneron Pharmaceuticals (REGN.US)$ with a buy rating, and adjusts the target price from $1,210 to $1,110.
According to TipRanks data, the analyst has a success rate of 58.8% and a total average return of 4.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Regeneron Pharmaceuticals (REGN.US)$'s main analysts recently are as follows:
Regeneron's third-quarter results surpassed expectations on revenue and more significantly in EPS. However, the performance of the Eylea franchise was a predominant concern. The impending introduction of a biosimilar version of Eylea's standard dose by a competitor casts doubt on the future of the franchise. This includes the potential underappreciated rate of erosion for the standard dose and possible impact on the high dose variant.
The recent decline in Regeneron's share value is viewed as an excessive response to the latest developments concerning Pavblu, the less than favorable projections for Q4 Eylea HD, and the absence of clear communication regarding future growth prospects for Eylea.
The recent decline in Regeneron's stock post-Q3 earnings took many by surprise, as it was thought that the near- and long-term consensus estimates for the ophthalmology franchise were overly optimistic. Despite this, it is believed that the intrinsic value of Regeneron's fundamentals remains significantly higher than the current share price.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
联博集团分析师William Pickering维持$再生元制药公司 (REGN.US)$买入评级，并将目标价从1,210美元下调至1,110美元。
根据TipRanks数据显示，该分析师近一年总胜率为58.8%，总平均回报率为4.2%。
此外，综合报道，$再生元制药公司 (REGN.US)$近期主要分析师观点如下：
Regeneron的第三季度业绩超出了营业收入和更重要的每股收益预期。然而，艾利雅（Eylea）特许经营业务的表现成为主要关注焦点。竞争对手即将推出艾利雅标准剂量的生物类似药版本，对特许经营业务的未来蒙上阴影。这包括标准剂量被低估的可能衰减速度以及对高剂量变体可能产生的影响。
Regeneron股价近期的下跌被视为对Pavblu最新发展的过度反应，以及对第四季度艾利雅高剂量（Eylea HD）不太乐观的预测，以及关于艾利雅未来增长前景的缺乏明确沟通。
Regeneron股票在第三季度营收后的最近下跌令许多人感到意外，因为人们认为眼科医疗特许经营业务的近期和长期共识估值过于乐观。尽管如此，人们认为Regeneron基本面的内在价值仍然远高于当前股价。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
